Printer Friendly

NEWVISION APPOINTS MANAGING DIRECTOR OF OPERATIONS IN THE UNITED KINGDOM

 BURLINGTON, Mass., Sept. 9 /PRNewswire/ -- NewVision Technology, Inc. (NASDAQ: VISN-Common; VISNW-Warrant) announced today that it has appointed Paul R. Hanke as managing director U.K. operations. L. James Miller who previously performed these functions will remain with the company as a consultant. Hanke will be responsible for managing the company's existing Laser Refractive Surgery Centers established pursuant to the company's joint venture agreement with British United Provident Association (BUPA) and for overseeing the company's operating plan in the U.K.
 Hanke has 16 years of management experience within the British Healthcare system. His experience includes the National Health Service as well as private sector Healthcare. For the past six years, Hanke has been employed by BUPA where he has had direct management responsibility for 10 BUPA hospitals generating over $75 million in revenue. He was successful in raising profits through cost reduction and income improvements. His most recent responsibilities at BUPA included strategic market development of BUPA's U.K. business as well as new business development within the European Economic Community.
 BUPA is the largest provider of private health care in the United Kingdom. It presently owns and operates healthcare facilities throughout England, Scotland, Wales and Northern Ireland.
 "We are very excited about the addition of Paul to our management team" stated William McLendon, president of NewVision. "His in-depth knowledge of the public and private health care system in the U.K. and his impressive professional achievements make him a valuable asset to our company. We expect Paul will make a significant contribution towards our goal of becoming the leading provider of laser refractive correction throughout the United Kingdom during 1993."
 The BUPA/NewVision centers utilize excimer lasers and a technique called photorefractive keratectomy (PRK) to correct common vision disorders such as nearsightedness, farsightedness and astigmatism now being treated with eyeglasses and contact lenses. Within the U.K., these conditions are estimated to affect more than 30 million people and presently account for in excess of $1.2 billion in annual corrective eye wear purchases and related examinations.
 The business of NewVision Technology, Inc. is to provide to its customers and partners in the ophthalmic community the safest and most efficacious technologies and techniques, coupled with sophisticated marketing and promotional support, for the correction of common vision disorders and to share in the revenue generated thereby.
 -0- 9/9/93
 /CONTACT: Lillian M. Boyle, investor relations for NewVision, 617-229-1100/
 (VISN)


CO: NewVision Technology ST: Massachusetts IN: MTC SU: PER

DD-CM -- NE005 -- 0164 09/09/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1993
Words:418
Previous Article:CYTOTHERAPEUTICS AND NEOCRIN ANNOUNCE AGREEMENT TO MERGE DIABETES PROGRAMS
Next Article:BOSTON TECHNOLOGY RESTATES QUARTERLY RESULTS FOR FY92 AND FY93; RESTATEMENT DOES NOT AFFECT RESULTS OF FULL FISCAL YEARS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters